{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:50:18Z","timestamp":1793332218831,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1053\/j.gastro.2022.05.055","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T11:01:43Z","timestamp":1654513303000},"page":"608-619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":305,"title":["Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial"],"prefix":"10.1053","volume":"163","author":[{"given":"William D.","family":"Chey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"M\u00e9graud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Laine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis J.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin W.","family":"Howden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2022.05.055_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection - the Maastricht V\/Florence consensus report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.05.055_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.05.055_bib3","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1053\/j.gastro.2021.02.014","article-title":"Impact of antimicrobial resistance rates on eradication of Helicobacter pylori in a US population","volume":"160","author":"Argueta","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.05.055_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/gutjnl-2020-321372","article-title":"European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients","volume":"70","author":"Nyssen","year":"2021","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.05.055_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/39.1.5","article-title":"The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection","volume":"39","author":"Erah","year":"1997","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1053\/j.gastro.2022.05.055_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/sjg.SJG_292_17","article-title":"Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?","volume":"23","author":"Graham","year":"2017","journal-title":"Saudi J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.05.055_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12768","article-title":"The appropriate cutoff gastric pH\u00a0value for Helicobacter pylori eradication with bismuth-based quadruple therapy","volume":"26","author":"Ke","year":"2021","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2022.05.055_bib8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/apt.15641","article-title":"Randomised trial of acid inhibition by vonoprazan 10\/20 mg once daily vs rabeprazole 10\/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study)","volume":"51","author":"Takeuchi","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.05.055_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9781212","article-title":"Efficacy and safety of vonoprazan-based vs proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials","volume":"2019","author":"Lyu","year":"2019","journal-title":"BioMed Res Int"},{"key":"10.1053\/j.gastro.2022.05.055_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12495","article-title":"Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori","volume":"23","author":"Li","year":"2018","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2022.05.055_bib11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1159\/000502287","article-title":"Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori","volume":"101","author":"Furuta","year":"2020","journal-title":"Digestion"},{"key":"10.1053\/j.gastro.2022.05.055_bib12","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00535-020-01709-4","article-title":"Clinical impact of vonoprazan-based dual therapy with amoxicillin for H.\u00a0pylori infection in a treatment-na\u00efve cohort of junior high school students in Japan","volume":"55","author":"Gotoda","year":"2020","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1053\/j.gastro.2022.05.055_bib13","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","article-title":"Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan","volume":"69","author":"Suzuki","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.05.055_bib14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1053\/j.gastro.2018.01.018","article-title":"Update on the use of vonoprazan: a competitive acid blocker","volume":"154","author":"Graham","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.05.055_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/ajg.2009.508","article-title":"Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability","volume":"105","author":"Luther","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.05.055_bib16","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"key":"10.1053\/j.gastro.2022.05.055_bib17","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.05.055_bib18","article-title":"Characterization of treatment practices for patients with newly diagnosed H pylori infection: a US population-based study using claims and electronic medical record data (Poster presentation; Sa252)","author":"Howden","year":"2021","journal-title":"Digestive Diseases Week (DDW)"},{"key":"10.1053\/j.gastro.2022.05.055_bib19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ypmed.2017.04.021","article-title":"Management of Helicobacter pylori in the United States: results from a national survey of gastroenterology physicians","volume":"100","author":"Murakami","year":"2017","journal-title":"Prev Med"},{"key":"10.1053\/j.gastro.2022.05.055_bib20","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1097\/MCG.0000000000001482","article-title":"Room for improvement in the treatment of Helicobacter pylori infection: lessons from the European Registry on: H.\u00a0pylori: Management (Hp-EuReg)","volume":"56","author":"Nyssen","year":"2022","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2022.05.055_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1523-5378.1996.tb00046.x","article-title":"Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection","volume":"1","author":"Harford","year":"1996","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2022.05.055_bib22","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1572-0241.1998.00602.x","article-title":"Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials","volume":"93","author":"Laine","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.05.055_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1053\/j.gastro.2022.05.055_bib25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.gastro.2021.03.045","article-title":"National and regional US antibiotic resistance to Helicobacter pylori: lessons from a clinical trial","volume":"161","author":"Hulten","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.05.055_bib26","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1007\/s10620-019-05694-4","article-title":"Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA","volume":"64","author":"Alsamman","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2022.05.055_bib27","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s11894-011-0226-4","article-title":"Gastric infection by Helicobacter pylori","volume":"13","author":"Sachs","year":"2011","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1053\/j.gastro.2022.05.055_bib28","doi-asserted-by":"crossref","unstructured":"Scott DR, Sachs G, Marcus EA. The role of acid inhibition in Helicobacter pylori eradication. F1000Res 2016;5:F1000 Faculty Rev-1747.","DOI":"10.12688\/f1000research.8598.1"},{"key":"10.1053\/j.gastro.2022.05.055_bib29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/antibiotics9100671","article-title":"Transitioning of Helicobacter pylori therapy from trial and error to antimicrobial stewardship","volume":"9","author":"Graham","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1053\/j.gastro.2022.05.055_bib30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0016-5085(92)90095-G","article-title":"Factors influencing the eradication of Helicobacter pylori with triple therapy","volume":"102","author":"Graham","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.05.055_bib31","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.3748\/wjg.v25.i32.4629","article-title":"Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing","volume":"25","author":"Pohl","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.05.055_bib32","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1053\/j.gastro.2021.07.012","article-title":"Comparison of culture with antibiogram to next-generation sequencing using bacterial isolates and formalin-fixed, paraffin-embedded gastric biopsies","volume":"161","author":"Hulten","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.05.055_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4385161","article-title":"Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial","volume":"2017","author":"Maruyama","year":"2017","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.05.055_bib34","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","article-title":"Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study","volume":"65","author":"Murakami","year":"2017","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.05.055_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12456","article-title":"Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: a multicenter, prospective, randomized trial","volume":"23","author":"Sue","year":"2018","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2022.05.055_bib36","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.04.012","article-title":"Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis","volume":"161","author":"Rokkas","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.05.055_bib37","unstructured":"Gatta L. Vonoprazan-based dual therapy and FDA-approved H.\u00a0pylori eradication regimens: a comparison of the available pooled data (Poster presentation; P2835). Annual Scientific Meeting and Postgraduate Course of the American College of Gastroenterology (ACG) 2020. October 23\u201328; Virtual."},{"key":"10.1053\/j.gastro.2022.05.055_bib38","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.05.055_bib39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/17425255.2018.1461835","article-title":"Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine","volume":"14","author":"El Rouby","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1053\/j.gastro.2022.05.055_bib40","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/00498254.2016.1203505","article-title":"In\u00a0vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker","volume":"47","author":"Yamasaki","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1053\/j.gastro.2022.05.055_bib41","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1124\/pr.112.007252","article-title":"Pharmacogenetics and cardiovascular disease--implications for personalized medicine","volume":"65","author":"Johnson","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1053\/j.gastro.2022.05.055_bib42","doi-asserted-by":"crossref","first-page":"13548","DOI":"10.3748\/wjg.v21.i48.13548","article-title":"First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype","volume":"21","author":"Saito","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.05.055_bib43","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.05.055_bib44","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/ctg.2015.18","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese\/non-Japanese subjects","volume":"6","author":"Sakurai","year":"2015","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1053\/j.gastro.2022.05.055_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12788","article-title":"Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy","volume":"26","author":"Eto","year":"2021","journal-title":"Helicobacter"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522006096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522006096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:50:51Z","timestamp":1762163451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508522006096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0016508522006096"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2022.05.055","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2022.05.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}